Gondola AMPS therapy
for medical professionals
Gondola AMPS therapy for medical professionals
With a neurological disorder such as a neurodegenerative disease (e.g., Parkinson’s disease), brain lesion (e.g., stroke) or chronic neurological condition (e.g., cerebral palsy), walking requires compensatory strategies to overcome the disability. These new walking compensations are demanding and increase the need for cognitive control. On the contrary, a healthy walking pattern is predominantly driven by automatic patterns with minimal cognitive control.
One way to enhance the automatic circuits and reduce cognitive control is through the somatosensory pathway. Somatosensory afferences are known to be essential for body representation and walking control. Specifically, somatosensory stimulation of the soles of the feet can improve walking and balance performance 1–4 and lead to plasticity in the central nervous system.
Gondola Medical Technologies has developed a novel non-invasive somatosensory stimulation therapy based on mechanical pressure pulses. The pulses are applied in two specific areas of both feet, the head of the big toe and the first metatarsal joint. The therapy comprises of four repetitions of a stimulation cycle that lasts 24
seconds, resulting in an overall therapy time of only 96
The stimulation cycles each consist of a six-second stimulation of the four specific target areas. This
approach is termed the Gondola “Automated Mechanical Peripheral Stimulation” (AMPS) therapy.
Somatosensory inputs (pressure and tactile inputs) are integrated and processed by the central nervous system, leading to a synaptic reinforcement within the sensory-motor system and improved walking and balance functions.
Learn more about the benefits of Gondola amps therapy
Therapy efficacy proofed in clinical research studies
Read the publications
Mechanism of Action
The mechanism believed to be associated with AMPS is an induced synaptic plasticity with strengthening of the neural circuits involved in walking automaticity. This hypothesis is supported by the clinical outcomes, the discovery of increased connectivity between brain regions involved in walking control, and an increase in brain-derived neurotrophic factor (BDNF) after AMPS.